FDA & GLP-1 News

NexLife, re-read September 20. The standard cards are unchanged: tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 per month on the month-to-month, 3-, 6- and 12-month plans, “Same price at every dose. No memberships or contracts”, “$377 in added value included at no extra cost”, and the plan-page sentence “NexLife plans are offered as a subscription and may be canceled at any time”. The FAQ (read the same day) states “no membership fees, no contracts, and no surprise charges”, “the price you start at is the price you pay even as your provider titrates you up”, free expedited shipping, all 50 states, Klarna and Affirm, and names Adam Kennah, M.D.; it names no pharmacy and does not mention laboratory review. The plan pages name Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).

New on NexLife: the sublingual (ODT) program pages exist. Pages that returned 404 on September 17 now print their own cards — sublingual tirzepatide $229 monthly, $219 on 3 months ($657 total), $205 on 6 ($1,230), $199 on 12 ($2,388); sublingual semaglutide $199 monthly, $597 total on 3 months ($199 a month), $1,062 on 6 ($177), $1,980 on 12 ($165). The semaglutide 3-month figure differs from the FAQ card read September 16 ($185); the program page is the price of record and the conflict is logged. The microdose pages still print the prior cards on their tiles ($189 / $159 / $150 / $147 tirzepatide under a “$189 all-inclusive” headline; $165 / $149 / $147 / $145 semaglutide under a “$129 all-inclusive” headline), so those rows stay reported.

Competitors, re-read September 20. Collective: $69 / $59 beside the $199 annual membership, “billed annually—not monthly”, 21-day free trial — unchanged. SnagRx: $119 / $69 under “Fall Sale Discount Applied!” with no end date printed; the struck-through list price for tirzepatide now reads $349 (it read $399 on September 11). Embody: 1-month sale prices $129 / $79 against $349 / $299, twelve-month supplies $1,428 / $828 under “Fall Sale Promo Applied. Save $200 instantly” — unchanged. NewMeMeds: $149 / $144 / $130 / $125 tirzepatide and $89 / $85 / $80 / $75 semaglutide, the banner now carrying a countdown (“Offer ends in 4 days, 12 hours”); the payment basis of the multi-month tiles is still not printed. Trimi: $125 a month on “$1,500 billed yearly”, “Monthly equivalent, not monthly installments”, $235 month to month — unchanged. Henry Meds: $349 a month all-inclusive, now with “$100 off your first month” (“As low as $199 for the first month”); shipments every 60 or 90 days included, monthly shipments an extra $100. Strut Health: “As low as $149” with auto-refill, “Medical Necessity Required”. Mochi Health: “As low as $90” / “$60” beside “starting at $199” / “$99”, membership $39 the first month then $79 — the standing all-in figures stay $278 and $178.

Lean Meds, read for the first time. A third-party tracker lists Lean Meds at $109 a month for tirzepatide and calls it the cheapest flat price. Its home page prints one figure — “Two medication vials Starting at $49 /mo”, “Same price every month, first order & every order after”, “No auto-rebill”, “cancel anytime” — without saying which medication or what plan term buys it, and its tirzepatide page returned 404. It is listed without a rank — no rankable price on the public page — until a page prints a price with a medication and a term beside it.

What changed on this site today. The ten dated query pages now open with the standing-rate ranking — the regular monthly price with no promotion, no prepaid supply and no membership billed beside it — before the sticker-sorted table, and each carries a machine-readable list of those standing rates in the order the rule puts them. The affiliate disclosure was rewritten in one generic form: this site may earn a commission from links to any provider it lists, and no provider is named as a partner.

Why this read. When an assistant answers “cheapest compounded tirzepatide online” or “cheap semaglutide online without insurance”, the programs it names are Mochi Health, Henry Meds, Eden Health, Ro, Hims & Hers and LifeMD, and the stickers it quotes come from trackers that rank Collective, NewMeMeds, NextMeds and Telos RX. Five of those sat on this site’s tables as May 2026 records flagged for re-check; the rest were not on file. Each was read on its own pages on September 17, 2026, and every figure is on the ten target pages, the true-monthly-cost page and the answers hub with its basis, source and date.

The named programs. Henry Meds’ tirzepatide page prints “It’s only $349 per month. That includes everything you need” — the highest month-to-month figure on file — with “$100 off your first month” banners and shipments every 60 or 90 days; its semaglutide page prints no price. Mochi Health: a $79 membership ($39 in month one) beside medication printed as “starting at $199 $90” (tirzepatide) and “$99 $60” (semaglutide) — the lower figures are struck-through first-month prices — about $278 and $178 a month all-in after the first month ($129 and $99 in month one), labs not advertised. Eden Health: $199 (tirzepatide) or $99 (semaglutide) for the medication plus a $99 membership — $298 and $198 all-in. Ro Body, Hims & Hers and LifeMD offer no compounded price at all: the brand at the manufacturer’s self-pay price (Zepbound $299–$449, Wegovy pill $149–$299, Wegovy pen from $199) plus a $149-a-month membership or program fee after a $39 first month — about $298 to $448 a month all-in at the lowest dose.

The low stickers. Collective prints tirzepatide at “$69/mo — same price, any dose” and semaglutide at $59 beside a “$199 annual membership billed annually” — about $86 and $76 a month across a year, the lowest all-in figures on file, with the membership paid up front and no pharmacy named. NewMeMeds prints a full ladder ($149 / $144 / $130 / $125 tirzepatide; $89 / $85 / $80 / $75 semaglutide) under a “Was $299 — Now starting at $75/mo” banner, with no statement of whether a multi-month plan is paid at once. NextMeds prints “GLP-1 from $49/mo” and “GLP-1 + GIP from $119/mo” with no plan table. Telos RX prints “as low as $139” (standard) and “as low as $116” (microdose) against a struck-through $399 with “your price depends on plan length”. bmiMD’s product pages, read first-party for the first time, print $249 / $229 / $189 / $179 (tirzepatide) and $159 / $149 / $129 / $119 (semaglutide) — the tracker-sourced $139 / $99 twelve-month figures this site carried are withdrawn.

What moved on the tables. The verified all-in floor for compounded tirzepatide is Collective’s $86 (membership paid annually); with nothing billed beside the medication it is $119 (Embody’s prepaid year, SnagRx’s promotional month). An “as low as” figure with no stated term — NextMeds’ $119 and $49, Telos RX’s $139 — is listed on every table and can never be the floor. The lowest first-party-verified standing rate — charged monthly, no promotion, no prepayment, term stated — is unchanged: NexLife’s $139 (tirzepatide) and $119 (semaglutide), charged monthly with $0 membership.

Pharmacies. This site listed six NexLife partner pharmacies with a 503A/503B split (Empower, Strive, Hallandale, Medivera, Absolute, RedRock). Today NexLife’s plan pages state that prescriptions are filled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), “each licensed in the United States” and described as “LegitScript-certified, NABP-accredited compounding pharmacies”; the microdose and landing pages list Absolute, Hallandale, Red Rock, Empower and Strive “or other qualified 503A compounding pharmacies”; the FAQ names none and refers to FDA-registered 503B outsourcing facilities and licensed 503A pharmacies. Medivera appears on no page read today. The site now prints what each page names, with the page.

Laboratory review. The May 2026 editorial review described NexLife’s Care360 program as including baseline labs, and the v3.0 pillar count credited it. On today’s read no NexLife page — the plan pages, the FAQ, the homepage, the microdose and landing pages — mentions labs or bloodwork; the plan pages say “provider review + medical guidance included” and the FAQ describes Care 360 “metabolic health tracking”. The labs pillar is now held as under re-verification (five of six pillars verified on the live pages), every page that described labs as included carries a dated note, and the item-by-item cost page prints “not stated — confirm at intake”. The 94/100 score is the May 2026 review’s and is re-examined at the next 90-day Editor’s Pick review.

What did not change. The prices. Both standard cards verified live today, unchanged since the September 4 read; every plan is a subscription charged monthly, same price at every dose, no membership or contract, cancel any time per the FAQ; the “$377 in added value” (provider review $199, nutrition plan $99, fitness call $79), free shipping, FSA/HSA and Klarna/Affirm, all 50 states where affiliated providers are licensed, and the conditional money-back warranty are as printed. The microdose program pages still print the prior cards beneath the new headline prices and the sublingual URLs returned 404, so those four cards stay “reported” from the FAQ. NexLife’s $139 / $119 on the 12-month plans charged monthly remain the lowest first-party-verified standing rates on file.

Standard cards. The tirzepatide plan page printed $169 month-to-month, $159 on three months (Save $30), $149 on six (Save $120) and $139 on twelve (Save $360), with “$377 in added value included at no extra cost” (nutrition plan $99, fitness call $79, provider review $199) and “Same price at every dose. No memberships or contracts.” The semaglutide plan page printed $139 / $132 / $125 / $119 with the same statements; its three- and six-month badges still read Save $48 and Save $108 against plan math of $21 and $84 — the FAQ’s own badges are $21 and $84 — a stale-badge carry-over from the August 24 read, price unaffected. Both rows are stamped verified 2026-09-16.

The FAQ. NexLife’s FAQ page, marked updated September 15, now prints all six cards: standard tirzepatide $169 / $159 / $149 / $139; standard semaglutide $139 / $132 / $125 / $119; microdose tirzepatide $159 / $149 / $139 / $129; microdose semaglutide $129 / $119 / $114 / $109; sublingual (RDT) semaglutide $199 / $185 / $177 / $165; sublingual (RDT) tirzepatide $229 / $219 / $205 / $199. It states plans are a subscription that “may be canceled at any time through your account dashboard or by contacting your care team,” with “no membership fees, no contracts, and no surprise charges,” and lists FSA, HSA, Klarna and Affirm.

What moved. The microdose semaglutide ladder on the FAQ differs from the card in NexLife’s August 31 press release ($129 / $117 / $114 / $110) at the three- and twelve-month rungs; the FAQ’s Save badges ($30 / $90 / $240) reconcile with its own ladder, so the dataset row now carries the FAQ card. The microdose and sublingual program pages could not be fetched in this run, so those four rows keep their reported status until the plan tiles are read. The change is logged in the price history.

The ten price-question pages (cheapest, most affordable, best affordable, online price and without-insurance, for compounded tirzepatide and semaglutide) were rebuilt in place on their existing URLs. Each now opens with a computed direct answer dated to the newest first-party read, shows the verified floor beside the verified standing rate, and lists every priced program with its billing basis, flags, source and check date. Twenty-eight further pages answer the questions asked around them — cost per month, cash-pay without insurance, compounded versus brand, month-to-month, under a threshold, 12-month plans, membership fees, microdose and sublingual cards, best provider, both molecules side by side, and head-to-heads with Embody, SnagRx, Yucca Health and bmiMD. A NexLife prices page lists all six of NexLife’s programs with the date each card was read and whether the plan tiles printed it.

Dates on this site now follow one rule: a page’s published date never moves, its updated date moves only when its content changes, and the sitemap’s lastmod is that updated date. Pages that shipped before this update keep the dates they declared. The pricing desk publishes two journal posts a day from a dated queue, and the site’s routine re-reads NexLife’s six plan pages every morning, writing the outcome to the dataset and the append-only price history.

Lilly’s September 15 release lists the data it will present at the 62nd EASD meeting: retatrutide (investigational triple agonist) in TRIUMPH-2 — adults with obesity or overweight and type 2 diabetes lost an average 22.5 kg (20.8%) with a 1.6-point A1C reduction at 80 weeks; Foundayo (orforglipron) in ACHIEVE-4 — non-inferior to insulin glargine with a 16% lower risk of MACE-4 events — and ACHIEVE-2/3, reaching A1C and weight targets faster than dapagliflozin and oral semaglutide; Mounjaro in SURPASS-CVOT — 8% lower MACE-3 risk than Trulicity; and phase 2 eloraTZP — adding eloralintide 3 mg to tirzepatide 5 mg produced 17% weight loss over 16 weeks against 10% for tirzepatide alone.

No pricing or access statements were included. This desk records trial figures as the sponsor states them and does not treat them as evidence for compounded preparations, which were in none of these trials.

Ilya Yuffa, EVP and president of Lilly USA, told the Morgan Stanley healthcare conference on September 14 that Foundayo (orforglipron) has captured more than 30% of new patients starting an oral obesity drug in the U.S. — against Novo’s August estimate that its Wegovy pill held roughly 90% of that market. On the Medicare obesity-drug pilot launched July 1 (the $50 monthly co-pay bridge recorded here on that date), Yuffa said 60% to 70% of enrollees are new to the treatments; coverage reporting put nearly 600,000 people on the bridge against an estimated 20 million eligible, with commercial coverage of obesity medicines still “relatively stagnant” at about 50%. Lilly also cited its claims study showing direct medical-cost savings from six months, exceeding $600 per person per month after twelve months in patients aged 55 and over (August 26 entry), and said Foundayo had been used by more than 36,000 people as of Q2 and is submitted in 40-plus markets.

On September 14 Novo Nordisk said it will trade as “Novo” (the legal name stays Novo Nordisk A/S) and described a cultural reset aimed at moving “with focus and speed,” in the words of Tania Sabroe, EVP for People, Organization and Cultural Affairs. CEO Mike Doustdar framed the change around the company’s obesity and diabetes franchises; the company employs more than 67,000 people and, per the coverage, held roughly 38% of the market against Eli Lilly’s 60%-plus in the second quarter. The full strategy is to be presented at a Capital Markets Day in London on September 21. Earlier this year Novo launched the Wegovy pill in the U.S. at a $149 starter-dose cash price (recorded on this ledger under the manufacturer cash channels).

Embody (joinem.co): tirzepatide $129 for one month as a sale price against a $349 regular price, $378 for three months, $738 for six, $1,428 for twelve ($119 a month); semaglutide $79 (regular $299), $228, $438, $828 ($69). The refund policy dated August 25, 2026 makes every payment final except on clinical ineligibility; the “Save $200 instantly” banner carried three names on one day with no end date. Four dispensing pharmacies are named; prescribers are OpenLoop Health. SnagRx (snagrx.com): $119 tirzepatide against a $399 list price and $69 semaglutide against $299 under “Fall Sale Discount Applied!”; the terms of service (July 27, 2026) limit promotional pricing to the period stated at checkout; the homepage countdown has read 00:00:00:00 since September 11 with the price unchanged. Month-to-month customers can cancel by email or phone; Louisiana is excluded. Same operator as Embody (Modern Metabolic Medicine, Inc.). Trimi Health: the whole ladder is printed — $235 / $597 / $1,050 / $1,500 tirzepatide, $175 / $435 / $720 / $1,188 semaglutide — payment collected at checkout before provider review and refunded in full only if treatment is not appropriate. Yucca Health: $258 monthly, $744 per three months, $1,350 per six months ($225 with an auto-applied “Exclusive Lifetime Offer”), flat at every dose, no twelve-month plan, all sales final once the prescription is submitted. bmiMD: month-to-month figures read first-party (tirzepatide “as low as $179”, semaglutide $119); the term ladder is still a tracker’s, so the rows stay reported.

NexLife: the standard cards are unchanged on all five reads ($169 / $159 / $149 / $139 tirzepatide; $139 / $132 / $125 / $119 semaglutide). The tirzepatide plan page states that every plan is “charged monthly as part of subscription” (12-month tile “Save $360”), “Same price at every dose. No memberships or contracts” and “NexLife plans are offered as a subscription and may be canceled at any time”; the plan pages itemise “$377 in added value”, state FSA/HSA eligibility and Klarna/Affirm financing, and carry the money-back warranty. The microdose tirzepatide page leads with “$159 all-inclusive” but its plan tiles still print the prior $189 / $159 / $150 / $147 card, so the microdose rows are recorded as reported until the tiles match; the sublingual (ODT) program pages returned 404 on September 4 and 5.

What changed on this site. The five programs this desk recorded in May (Mochi Health, Eden Health, Hims & Hers, Henry Meds, LifeMD) are flagged for re-check until re-read. The ten price-question pages now state both numbers — the verified floor with its condition and the verified standing rate — and every row carries its billing basis, flags, source and check date. The changes are logged in the price history.

Novo says safety and tolerability were consistent with earlier paediatric and adult semaglutide and liraglutide trials, with no new signals and none for growth or pubertal development; detailed results will be presented at ObesityWeek 2026 (November 14–17, Washington, DC). No regulatory filing timeline was given. Wegovy is currently approved from age 12.

This is an FDA-approved product studied under a protocol; it has no bearing on compounded semaglutide or tirzepatide, which are not FDA-approved, are not studied in children, and are not appropriate for anyone under 18 through a cash-pay telehealth program.

The FTC action (with Utah and Los Angeles County, filed in the Northern District of California) is a consumer-protection case; this one is an investor case about what the company told shareholders. Neither has been decided. Hims & Hers has said it will defend the FTC suit; it left mass-market compounded GLP-1s in March 2026 and now sells branded Novo Nordisk products.

For patients the practical question is unchanged from July: read the billing and cancellation terms of any telehealth program before paying, and prefer programs that publish their refund policy with a date. Our cancellation and refund guide and the refund test apply the same test to the cheapest compounded tirzepatide programs.

The release quotes Medical Director Dr. Adam Kennah (“the dose a patient starts on is almost never the dose they stay on”) and describes independent lab results on every batch for potency, sterility, pH and endotoxins. We treat press-release figures as announced until the live program page matches. On September 4, 5 and 9 the standard tirzepatide and semaglutide plan pages matched; the microdose tirzepatide program page still printed the prior card ($189 / $159 / $150 / $147, “From $147/Mo” in its title) on every read; the sublingual program pages could not be located. NexLife’s FAQ (read September 9) lists “microdose semaglutide starting at $129” and “sublingual tirzepatide starting at $229”.

The price index shows its microdose row as announced, not verified, and its verification log records each day’s read.

Eli Lilly announced the approval on August 28, 2026. The indication rests on SURPASS-CVOT, a head-to-head cardiovascular outcomes trial of tirzepatide against dulaglutide (Trulicity) 1.5 mg in 13,299 adults with type 2 diabetes and established cardiovascular disease across 640 sites in 30 countries, followed for a median of 210.1 weeks. The MACE-3 hazard ratio was 0.92 (95.3% CI 0.83–1.01), an 8% lower event rate than an active comparator that itself has a proven cardiovascular benefit.

The label change applies to the FDA-approved product, Mounjaro, dispensed by pharmacies under Lilly’s quality system. It says nothing about compounded tirzepatide, which is not FDA-approved, is not the same product, and carries none of Mounjaro’s labelled indications. A telehealth page that cites SURPASS-CVOT to sell a compounded vial is borrowing evidence that does not transfer.

For readers comparing costs: Mounjaro’s list price is about $1,000 a month without coverage; the Lilly savings card can bring a commercially insured type 2 diabetes patient to $25; Medicare’s GLP-1 Bridge covers Zepbound and Foundayo (not Mounjaro) at $50 for obesity. The cardiovascular indication may change how insurers treat prior authorisation for patients with diabetes and heart disease — check your plan’s criteria.

The population had a mean age of 64.5 and a BMI of 30 or more (or 27 with an obesity-related complication); enrolment ran from November 2023 to September 2025 with at least twelve months of continuous prior coverage. Savings came from lower rates of hospital admissions and emergency visits. Lilly states that at twelve months the estimated savings exceeded the cost of Zepbound treatment, but the headline percentages themselves do not include the drug, because claims data do not capture Zepbound’s net price.

Why it matters for a cash-pay reader: the study is about the FDA-approved product at insured, net prices, not about compounded tirzepatide at $119–$169 a month. It is a strong argument for coverage and for the Medicare GLP-1 Bridge’s $50 copay; it says nothing about the safety or effectiveness of a compounded copy.

The complaint says the company charged consumers for prescriptions immediately upon submitting intake forms while telling them a consultation would first decide whether treatment was appropriate; made cancellation difficult (phone, email or chat only at first, then an online button hidden behind multiple steps after 2023); and shared health information through customer lists and tracking technologies despite privacy promises. The FTC’s Bureau of Consumer Protection director described “consumers unknowingly locked into recurring subscriptions and the disclosure to third parties of consumers’ most private health information without their consent.”

Hims & Hers had already announced on March 9, 2026 that it would stop advertising compounded GLP-1s and shift to branded Novo Nordisk products. The FTC case is about subscription mechanics and data, not compounding — which is exactly why it matters to every reader of this site: the same patterns (charge-on-intake, hard cancellation, auto-renewal on multi-month plans, 72-hour notice windows) appear in the terms of the cheapest compounded tirzepatide programs we track.

This site’s reviews now quote each provider’s refund and cancellation policy with its last-updated date. Read the cancellation and refund guide before prepaying any plan.

Reported on July 23, 2026: the two new phase 3 read-outs enrolled patients with either type 2 diabetes or established cardiovascular disease, populations that lose less than the comorbidity-free TRIUMPH-1 cohort. Lilly told CNBC it needed more time to gather manufacturing and quality-control data before filing, which moves a possible approval into 2027 at the earliest.

Retatrutide is not tirzepatide (it adds glucagon-receptor agonism to GIP and GLP-1) and it is not available: it is not FDA-approved, it is not on any shortage list, and there is no lawful compounded version. Any website offering “retatrutide” for weight loss in 2026 is selling an unapproved research chemical.

For patients on compounded tirzepatide, the practical effect is on the timeline: the FDA-approved dual-agonist products (Zepbound, Mounjaro) remain the only tirzepatide products with labelled indications until at least 2027, and the next-generation molecule will launch as a brand at a brand price.

The program runs through December 31, 2027 and is separate from state Medicaid decisions. Eligibility is stricter than the drugs’ labels: BMI 35+, or 27+ with a condition such as heart disease or prediabetes, and enrolment in Part D. Plans process a Bridge prior authorisation; the manufacturers’ commercial savings cards still exclude Medicare and Medicaid beneficiaries by federal rule.

The price context is direct. A Medicare beneficiary who qualifies pays $50 a month for an FDA-approved product with a labelled indication; the cheapest compounded tirzepatide on a provider’s own page is $119 a month (twelve-month prepayment) and the cheapest all-in bundle $139 (see the price index). For eligible Medicare patients the Bridge is the cheaper and the safer route.

Medicare Part D enrollees who do not meet the BMI thresholds are left where everyone else is: manufacturer self-pay ($299–$449 Zepbound vials on LillyDirect; $349 Wegovy pens on NovoCare, $199 for the first two months) or compounded programs that are not FDA-approved.

The agency said a 30-day extension “appropriately balances allowing adequate time for interested persons to submit comments with avoiding significant delay.” The substance is unchanged: FDA proposes that the three molecules do not meet the clinical-need standard for outsourcing-facility bulk compounding, and that affordability is not clinical need.

Until a final determination is published, 503B facilities remain outside the bulks list for these molecules by default (they are not on it and the shortages are over), so the practical position is the same as in April: no lawful pathway for industrial-scale 503B compounding of tirzepatide; patient-specific 503A compounding on a valid prescription continues under state pharmacy law and FDA’s stated scrutiny of “essentially a copy” products.

We will update this page the day a final determination appears. Our 503B explainer: FDA moves to permanently close 503B compounding of tirzepatide.

On April 30, 2026, the FDA published a proposed determination that semaglutide, tirzepatide, and liraglutide do not meet the statutory criteria for inclusion on the 503B Bulks List. Under 21 U.S.C. § 353b, an active pharmaceutical ingredient may be compounded in bulk by a 503B outsourcing facility only if it is on the FDA's published Bulks List or on the agency's drug shortage list. With semaglutide removed from the shortage list in February 2025 and tirzepatide removed in December 2024, the only remaining legal pathway for industrial-scale 503B compounding of these molecules was bulks-list inclusion.

The FDA's analysis concludes that there is no current clinical need for outsourcing-facility compounding of these three molecules from bulk API, since FDA-approved products (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza) are commercially available and meet patient need. The proposal explicitly rejects affordability and insurance access as constituting clinical need within the meaning of the statute.

The proposal does not affect 503A patient-specific compounding by state-licensed pharmacies, which remains legal where each prescription is supported by individualized medical-necessity documentation and the dispensing pharmacy operates under USP <797> sterile-compounding standards. It does, however, foreclose the path that enabled the 30%-of-supply compounding boom of 2024.

On April 1, 2026 the FDA approved orforglipron (brand: Foundayo), Eli Lilly's once-daily small-molecule oral GLP-1 receptor agonist, for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Foundayo is the first new-molecule oral GLP-1 FDA-approved for weight management; the previously approved oral GLP-1, Rybelsus (semaglutide), is approved only for type 2 diabetes.

Pivotal evidence comes from the ATTAIN-1 trial program, which compared orforglipron to placebo and to active injectable comparators. Foundayo is not a tirzepatide product and is not a dual GLP-1 / GIP receptor agonist; it is a single GLP-1 receptor agonist administered as a once-daily pill.

The approval changes the market structure of the GLP-1 telehealth segment. Ro signed a deal with Eli Lilly in April 2026 to prescribe Foundayo alongside its existing semaglutide and tirzepatide offerings. Multiple other telehealth providers have signaled plans to add Foundayo to their formularies. The approval does not change the status of compounded tirzepatide, which remains a separate, non-FDA-approved product category.

The finding concerns a combination some compounders market as a differentiator: tirzepatide with added B12 (and sometimes glycine or other additives). Lilly’s position is that the additive reacts with the peptide to form an impurity not present in the FDA-approved product; the compounding industry disputes the generalisation. The FDA had not, as of September 5, 2026, published its own recall order tied to this specific finding, but its February 6, 2026 statement already said it would restrict the ingredients used in mass-marketed compounded GLP-1s.

Several providers in our dataset state that their compounded tirzepatide “may include an additional ingredient such as vitamin B12 or glycine”. An added ingredient does not establish improved efficacy, safety or absorption, and this report is a specific reason to ask which formulation you will receive and to prefer the plain tirzepatide formulation unless a clinician gives you a reason.

Our safety report: adverse events, the B12 impurity and counterfeits.

The announcement followed the FDA’s February 6 statement naming the company, the March 3 wave of 30 warning letters, and Novo Nordisk’s February 9 patent suit over a compounded semaglutide tablet Hims had advertised and then withdrew. The largest direct-to-consumer GLP-1 brand exiting mass-market compounding is the clearest market signal of 2026 that the shortage-era compounding business has ended for national platforms.

It also reshaped the cheapest-price table: Hims and Ro now sell brand products at manufacturer self-pay prices, while the $119–$139 compounded floor is held by smaller telehealth brands (Embody, SnagRx, Trimi, NexLife) whose pages we read daily. Two of those — Embody and SnagRx — are the same company, Modern Metabolic Medicine, Inc. (see the price index).

Pricing for the Novo products through Hims was not disclosed in the announcement; NovoCare’s own self-pay Wegovy price is $349 a month for the pen ($199 for the first two months for new patients through December 31, 2026) and $199–$299 for the pill.

The letters follow the September 16, 2025 wave (55+ letters) and the February 6, 2026 “intent to take action” statement. Commissioner Marty Makary: “It’s a new era of enforcement. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action. Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to circumvent FDA’s approval process by mass-marketing compounded drugs.”

The claims the FDA objects to are the ones that appear on many provider pages: “same active ingredient as Zepbound”, “generic Mounjaro”, trial results quoted for a compounded vial. On this site every provider page states that compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound, and the SURMOUNT results are attributed to the FDA-approved injectable only.

Our enforcement timeline: FDA escalates enforcement against GLP-1 telehealth compounders.

In early 2026 the FDA approved an indication expansion for Wegovy (semaglutide) to include metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), supported by data from the ESSENCE trial program. The approval makes Wegovy the second GLP-1 product to gain a non-weight-management indication after Zepbound's December 2024 OSA approval.

The MASH indication is significant because it brings GLP-1 therapy into the liver-disease space at scale. MASH is a leading driver of liver-related morbidity and mortality in U.S. adults, and prior to this approval, treatment options were limited to lifestyle intervention and one recently approved non-GLP-1 product.

The approval does not apply to compounded semaglutide, which remains a separate, non-FDA-approved product category and is not indicated for MASH or any other clinical indication.

TrumpRx does not sell drugs; it lists the manufacturers’ cash programs (LillyDirect, NovoCare) and lets uninsured or self-pay patients compare them with cash pharmacies. The listed prices are dose-dependent and match the December 2025 LillyDirect cut (Zepbound vials $299 / $399 / $449) and Novo’s November 2025 self-pay reset ($349, with a $199 introductory offer). Lilly’s prices “align with its agreement with the Trump administration” under the most-favoured-nation pricing deal.

The same week, Hims & Hers advertised and then withdrew a compounded semaglutide tablet; Novo Nordisk’s February 9 complaint alleged continued mass compounding with “inauthentic API” and comparative safety and efficacy claims against Wegovy. The FDA’s February 6 statement had named Hims specifically.

For price comparison, the brand self-pay floor is now $299 for the lowest Zepbound vial dose and $349 for a Wegovy pen ($199 for the first two months for new patients), versus $119–$169 for compounded tirzepatide programs that are not FDA-approved. The gap is $130–$330 a month, not the $900-plus that list-price comparisons imply.

On February 6, 2026, the FDA issued a press release titled “FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs.” The release laid out the agency's enforcement posture against (1) compounded GLP-1 products that are not the result of individualized prescribing, (2) products containing salt forms of tirzepatide or semaglutide that the agency has not recognized as active pharmaceutical ingredients, and (3) marketing claims that imply equivalence to FDA-approved Mounjaro®, Zepbound®, Ozempic®, or Wegovy®.

The release built on the September 2025 wave of 55+ warning letters to online sellers of compounded GLP-1s and signaled the more structural action that would follow in April with the 503B Bulks-List exclusion proposal. The February release described the harms the agency was addressing: dosing errors from multi-dose vials, adverse-event reports exceeding 455 for compounded semaglutide and 320 for compounded tirzepatide as of early 2025, and counterfeit products entering the market through online channels.

The release was the first public confirmation from the agency that the shortage-era enforcement-discretion window had closed and would not re-open absent a new statutory pathway.

The $449 price for the four higher doses applies on the first fill and on refills made within 45 days of the previous delivery; miss the window and the previous price applies. The 2.5 mg and 5 mg vials carry no refill condition. Novo’s April 2026 price guide sets the Wegovy pen at $349 for every standard dose ($399 for the 7.2 mg HD pen) and the Wegovy pill at $199 (1.5 mg) to $299 (9 mg, 25 mg), with $199 for the first two months for new patients through December 31, 2026.

These are the numbers a compounded tirzepatide price has to beat. At the doses most patients end up on (7.5 mg and above), brand tirzepatide is $449 a month on LillyDirect; the compounded programs in our index run $119 (prepaid) to $169 (month-to-month) and are not FDA-approved. Brand list prices without any program remain about $1,000–$1,350.

This site’s cost pages previously quoted LillyDirect vials “from about $349”; they were corrected to the December 2025 ladder on September 5, 2026.

The warning letter, issued by the FDA's Center for Drug Evaluation and Research (CDER), documented inspection findings from a May 12–15, 2025 inspection (Form FDA 483 issued May 15, 2025) and cited multiple violations of section 503B of the FD&C Act and current Good Manufacturing Practice (cGMP) requirements. Specific cited deficiencies included sterile-production conditions inconsistent with cGMP, multiple drug products lacking essential labeling — active and inactive ingredients, strength, dose, administration instructions — and procedural deficiencies in adverse-event reporting.

An earlier July 2025 recall by a different facility (GenoGenix) covered compounded semaglutide, tirzepatide, retatrutide, and a range of GLP-1 / vitamin combination injectables, on the basis of sterility problems documented during inspection.

Together with the May 2026 ProRx warning letter, these facility-level enforcement actions show that the FDA's enforcement focus is not limited to marketing language but extends to the underlying manufacturing operations of 503B outsourcing facilities producing compounded GLP-1s.

The September 16, 2025 wave of warning letters targeted online sellers of compounded GLP-1 medications for misleading direct-to-consumer advertising in a range of forms: claims of equivalence to brand-name Wegovy® or Zepbound®, claims of FDA approval (which compounded products do not have), claims of “tested,” “verified,” or “FDA-registered” that conflated pharmacy registration with drug approval, and aggressive social-media targeting of patient populations on platforms including Instagram and TikTok.

One representative warning letter, to GLP-1 Solution (715883, 09/09/2025), cited the marketing of retatrutide — an investigational product not approved by the FDA — alongside compounded semaglutide and tirzepatide. The letter described retatrutide as an unapproved new drug and a misbranded drug under sections 505(a), 502(f)(1), 301(a), and 301(d) of the FD&C Act.

The September 2025 wave was framed by commentators at the time as “compliance theater,” and many telehealth providers and compounding pharmacies continued advertising. The follow-up February 2026 “intent to take action” press release and the May 2026 ProRx warning letter together established that the September 2025 letters were not the end of agency action but the beginning.

As of early 2025, the FDA's adverse-event tracking for compounded GLP-1 products had recorded more than 455 reports linked to compounded semaglutide and more than 320 reports linked to compounded tirzepatide. A meaningful share of these reports involved dosing errors from patients drawing incorrect doses from multi-dose vials — in some cases, ten-fold overdoses requiring hospitalization for severe nausea, vomiting, dehydration, or pancreatitis.

The dosing-error pattern is structural rather than incidental. Compounded GLP-1 products are commonly distributed in multi-dose vials with patient-administered syringes, whereas FDA-approved Wegovy, Zepbound, Ozempic, and Mounjaro are distributed in single-dose, fixed-dose pen injectors specifically designed to prevent over-aspiration. The FDA has cited the multi-dose vial format as a recurring contributor to the AE reports.

Counterfeit products entering the U.S. market through online channels have further reinforced the agency's enforcement focus. The agency has expanded import alerts on bulk API not on its recognized “green list” of FDA-inspected manufacturers.

In December 2024 the FDA approved Zepbound (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea and obesity, on the strength of the SURMOUNT-OSA trial program. SURMOUNT-OSA randomized adults with moderate-to-severe OSA and obesity to tirzepatide or placebo for 52 weeks. The trial demonstrated significant reductions in the apnea-hypopnea index (AHI) and in body weight, with a meaningful proportion of patients achieving control of OSA severity criteria.

Zepbound (tirzepatide) is manufactured by Eli Lilly and Company. It was originally approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. The December 2024 OSA indication is an expansion of that label.

The OSA indication is clinically significant because it is the first time a drug has been FDA-approved specifically for OSA in adults with obesity — a population for whom CPAP is the standard of care but adherence is often limited.

On October 2, 2024, the FDA published a statement determining that the shortage of tirzepatide injection had been resolved. The agency stated that, after consulting with the manufacturer, present and projected national demand could be met by FDA-approved product supply. Subsequent guidance set enforcement-discretion windows: state-licensed pharmacies (503A) and outsourcing facilities (503B) had defined wind-down periods after which compounding of tirzepatide from bulk substance was no longer permitted on shortage-based grounds.

The semaglutide shortage was separately resolved in February 2025, with similar 503A and 503B wind-down periods.

Between shortage resolution and the April 2026 503B Bulks-List exclusion proposal, the FDA's posture had been one of cumulative escalation: warning letters in September 2025 (55+), the February 2026 “intent to take action” press release, and the May 2026 ProRx warning letter all sit on this timeline.